Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether docetaxel is more effective when given alone or together with vandetanib.

PURPOSE: This randomized phase II trial is studying docetaxel given together with or without vandetanib to see how well it works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.


Options:
A: Arm Label: non platinum based chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Arm Label: platinum based chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: stealth liposomal doxorubicin, Drug: carboplatin, Drug: paclitaxel, Drug: Topotecan, Drug: Gemcitabine | Intervention Type: DRUG; Name: stealth liposomal doxorubicin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): non platinum based chemotherapy, platinum based chemotherapy
B: Arm Label: Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Triple-negative Breast Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: BRCA- positive Ovarian Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): BRCA- positive Ovarian Cancer: Cyclophosphamide Alone, BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Non-Hodgkin's: Cyclophosphamide Alone, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: Cyclophosphamide Alone
C: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: docetaxel, Drug: vandetanib | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: vandetanib; Assigned to Arm(s): Arm I, Arm II

Answer: D